<DOC>
	<DOCNO>NCT01015040</DOCNO>
	<brief_summary>The objective study compare relative bioavailability pharmacokinetics solifenacin succinate suspension versus tablet .</brief_summary>
	<brief_title>Relative Bioavailability Study Solifenacin Succinate Liquid Suspension ( Fed Fasting ) Versus VESIcare Tablet ( Fasting ) Healthy Volunteers</brief_title>
	<detailed_description>All subject participate treatment separate minimum ( = &gt; minimum ) 13 day dose . In two fasting period , subject receive solifenacin succinate orally treatment period follow minimum 10 hour fast food beverage . In fed condition , subject receive suspension within 30 minute start breakfast .</detailed_description>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Healthy subject weigh least 45 kg Body Mass Index ( BMI ) 1832 kg/m2 , inclusive If female , subject least 2 year postmenopausal , surgically sterile practice effective birth control lactate pregnant Medically healthy , normal 12lead electrocardiogram ( ECG ) Good venous access arm History clinically significant disease malignancy exclude nonmelanoma skin cancer Known hypersensitivity VESIcareÂ® excipients formulation , history severe allergic anaphylactic reaction History alcoholism substance abuse within past 2 year Has use tobaccocontaining product nicotine nicotine containing product within six month Supine mean systolic blood pressure &lt; 90 &gt; 160 mmHg mean diastolic blood pressure &lt; 50 &gt; 90 mmHg , pulse rate &lt; 40 &gt; 100 beat per minute Positive test hepatitis C virus ( HCV ) antibody hepatitis B surface antigen ( HBsAg ) Known positive human immunodeficiency virus ( HIV ) antibody Clinical laboratory test outside normal limit Treatment prescription nonprescription drug , include complementary alternative medicine overthecounter medication , exception oral contraceptive , hormone replacement therapy , occasional use acetaminophen within 14 day prior Day 1 Inability abstain alcohol caffeine use 48 hour prior administration first dose study drug throughout duration study grapefruit , Seville oranges , star fruit , product contain item 72 hour prior administration first dose study drug throughout duration study Donated one unit blood , significant blood loss , receive transfusion blood blood product within 60 day donate plasma within 7 day prior study checkin Any clinically significant history gastrointestinal symptom nausea , abdominal discomfort upset , heartburn four week prior study checkin history gastrointestinal surgery except appendectomy cholecystectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>solifenacin succinate</keyword>
	<keyword>VESIcare</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>